Employers Pairing GLP-1 Medications with Lifestyle Adjustments for Enhanced Health Benefits | |
In the face of a rising obesity rate affecting 40% of the U.S. population, recent advancements in medication offer a new avenue for weight management. GLP-1 drugs, initially prescribed for diabetes, have gained FDA approval for weight loss, with Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound leading the charge. However, their high cost, approximately $1,000 per month per patient, raises questions about coverage, especially since nearly 60% of Americans rely on employer-provided health insurance. | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: All States Target City : Carlsbad Last Update : Jan 16, 2025 6:00 AM Number of Views: 5 | Item Owner : hrviews Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Click here to read some tips. |